[Astragalus polysaccharide combined with cisplatin inhibits growth of recurrent tumor and down-regulats the expression of CD44, CD62P and osteopontin in tumor tissues in mice bearing Lewis lung cancer].

Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi

Gansu University of Chinese Medicine, Institute of Integrative Traditional Chinese and Western Medicine, Gansu University of Traditional Chinese Medicine, Provincial Key Laboratory of Molecular Medicine and Prevention and Treatment of Major Diseases with Traditional Chinese Medicine in Gansu Colleges and Universities, Gansu Provincial Laboratory of Chinese Medicine Pharmacology and Toxicology, Lanzhou 730000, China. *Corresponding author, E-mail:

Published: December 2018

Objective To investigate the effects of Astragalus polysaccharide (APS) combined with cisplatin (DDP) on the pathological morphology of recurrent tumor and the expression of metastasis-related proteins CD44, CD62P and osteopontin (OPN) following Lewis lung carcinoma (LLC) surgery. Methods LLC cell suspension was injected subcutaneously into palmula of left hind limb of C57BL/6J mice as a tumor-supply group. The other 80 mice were randomized into 8 groups: model group, APS-treated groups at different concentrations of 50, 100 and 200 μg/mL, 6 mg/kg DDP-treated group, and 3 mg/kg DDP combined with 50, 100, 200 μg/mL APS-treated groups. The palmula tumor cells were collected from the tumor-supply group 10 days after LLC injection and then injected subcutaneously into all of the 80 mice to establish the recurrent and metastatic mouse models of lung cancer. Subsequently, corresponding different substances were administrated intraperitoneally in the different treated groups since the next day. After 15 days' administration, all the mice were sacrificed by cervical spine dislocation. Morphological characteristics were observed by H&E staining, and the protein expression of CD44, CD62P and OPN were measured by immunohistochemistry. Results Compared with the model group, the pathological changes of the recurrent tissues in each treatment group were alleviated to some extent, especially in the DDP combined with 200 μg/mL APS group; the expression of CD44, CD62P and OPN in each treatment group decreased, especially in the DDP group and DDP combined with 100 and 200 μg/mL APS-treated groups. Conclusion APS combined with DDP could significantly inhibit the growth and metastasis of Lewis lung cancer cells, which might be associated with the reduced expression of CD44, CD62P and OPN.

Download full-text PDF

Source

Publication Analysis

Top Keywords

cd44 cd62p
20
expression cd44
16
200 μg/ml
16
lewis lung
12
aps-treated groups
12
100 200
12
ddp combined
12
cd62p opn
12
group
9
combined cisplatin
8

Similar Publications

Biomimetic Nanosystem Loading Aggregation-Induced Emission Luminogens and SO Prodrug for Inhibiting Insufficient Photothermal Therapy-Induced Breast Cancer Recurrence and Metastasis.

Adv Sci (Weinh)

September 2024

School of Science and Engineering, Shenzhen Institute of Aggregate Science and Technology, The Chinese University of Hong Kong, Shenzhen (CUHK-Shenzhen), Guangdong, 518172, China.

Photothermal therapy (PTT) holds considerable clinical promise. However, insufficient PTT-induced tumor recurrence and metastasis is an urgent practical problem that needs to be solved. Herein, a biomimetic mesoporous organosilicon nano-system called PSAB is designed to precisely deplete cancer stem cells (CSCs) and prevent tumor recurrence and metastasis after PTT.

View Article and Find Full Text PDF

Biomimetic platelet-like nanoparticles enhance targeted hepatocellular carcinoma therapy.

Colloids Surf B Biointerfaces

August 2024

School of Basic Medical Sciences, Southwest Medical University, Luzhou, Sichuan 646000, China. Electronic address:

Curcumin (CUR) is a promising natural product for hepatocellular carcinoma (HCC) therapy. However, its clinical application has been limited by some issues such as rapid clearance and inadequate tumor accumulation. To address these drawbacks, we developed platelet membrane-coated CUR-loaded PLGA nanoparticles (PCPNPs).

View Article and Find Full Text PDF

Cisplatin-loaded mesoporous polydopamine nanoparticles capped with MnO and coated with platelet membrane provide synergistic anti-tumor therapy.

Int J Pharm

May 2024

College of Biological Science and Medical Engineering, Shanghai Engineering Research Center of Nano-Biomaterials and Regenerative Medicine, Donghua University, Shanghai 201620, PR China. Electronic address:

A multifunctional nanoplatform was constructed in this work, with the goal of ameliorating the challenges faced with traditional cancer chemotherapy. Cisplatin (CP) was loaded into mesoporous polydopamine (mPDA) nanoparticles (NPs) with a drug loading of 15.8 ± 0.

View Article and Find Full Text PDF

Presently, the commonly used anti-tumor drugs lack targeting ability, resulting in a limited therapeutic efficacy and significant side effects. In this view, platelet membranes (PMs) not only exhibit specific binding of its P-selectin protein with CD44, which is highly expressed on breast cancer cells, to promote tumor-active targeting by PM biomimetic nanoplatforms, but also respond to vascular damage, thus inducing biochemotactic targeting to further facilitate the aggregation of these nanoplatforms. Therefore, in this study, a PM was applied to construct a biochemotactic-targeting nanotherapeutic platform based on dendritic large pore mesoporous silica nanoparticles (DLMSNs) co-loaded with chlorin e6 (Ce6) and lapatinib (LAP) to achieve the combination of photodynamic therapy (PDT) and EGFR inhibition therapy for breast cancer.

View Article and Find Full Text PDF

Background: Neovascular age-related macular degeneration (nAMD) is a major cause of blindness in the elderly. The disease is due to the growth of abnormal blood vessels into the macula, leading to the loss of central vision. Intravitreal injection of vascular endothelial growth factor (VEGF) inhibitors (e.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!